In addition, we showed that CAF-1/p60 and p150 subunits are involved in HR-DDR, thus indicating the chance to induce a radiosensitizing synthetic lethality mechanism by treating tumour cells pharmacologically inhibited for CAF-1/p60 and p150 with PARP inhibitors, in OSCC patients in the worse prognostic group, in the direction of a truly personalized therapy. This evidence concerns the gene PARP1 and neoplasm.